Cogent Biosciences Inc

Change company Symbol lookup

Select an option...

COGT Cogent Biosciences Inc

TOP TOP Financial Group Ltd

VEEV Veeva Systems Inc

ETY Eaton Vance Tax-Managed Diversified Equity Income Fund

FDX FedEx Corp

TARO Taro Pharmaceutical Industries Ltd

TIO Tingo Group Inc

BEAT Heartbeam Inc

KO Coca-Cola Co

IHRT iHeartMedia Inc

Go

Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.